Clinical Trial Update: Chronic, Low Dose Erythropoetin Beta in Ischemic Cardiomyopathy [Phase 4]

View source ↗

Summary

A Phase 4 clinical trial evaluating chronic, low-dose erythropoietin beta for ischemic cardiomyopathy has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ischemic Cardiomyopathy

Drugs mentioned

• erythropoietin beta (erythropoietin beta)

Snippet

Sponsor: Charite University, Berlin, Germany | Conditions: Ischemic Cardiomyopathy | Phase 4 | Status: COMPLETED